HRP20231438T1 - Formulacije oksitocina koje sadrže magnezij i načini uporabe - Google Patents
Formulacije oksitocina koje sadrže magnezij i načini uporabe Download PDFInfo
- Publication number
- HRP20231438T1 HRP20231438T1 HRP20231438TT HRP20231438T HRP20231438T1 HR P20231438 T1 HRP20231438 T1 HR P20231438T1 HR P20231438T T HRP20231438T T HR P20231438TT HR P20231438 T HRP20231438 T HR P20231438T HR P20231438 T1 HRP20231438 T1 HR P20231438T1
- Authority
- HR
- Croatia
- Prior art keywords
- pain
- oxytocin peptide
- magnesium
- magnesium salt
- oxytocin
- Prior art date
Links
- 101800000989 Oxytocin Proteins 0.000 title claims 24
- 239000000203 mixture Substances 0.000 title claims 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title claims 6
- 229910052749 magnesium Inorganic materials 0.000 title claims 6
- 239000011777 magnesium Substances 0.000 title claims 6
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 title 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title 1
- 229960001723 oxytocin Drugs 0.000 title 1
- 208000002193 Pain Diseases 0.000 claims 17
- 159000000003 magnesium salts Chemical class 0.000 claims 13
- 230000036407 pain Effects 0.000 claims 13
- 229940091250 magnesium supplement Drugs 0.000 claims 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 4
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010016059 Facial pain Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 101500028587 Homo sapiens Oxytocin Proteins 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 2
- 206010028836 Neck pain Diseases 0.000 claims 2
- 208000007613 Shoulder Pain Diseases 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 230000036592 analgesia Effects 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 210000004889 cervical nerve Anatomy 0.000 claims 2
- 230000001667 episodic effect Effects 0.000 claims 2
- 239000012669 liquid formulation Substances 0.000 claims 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 2
- 229960005336 magnesium citrate Drugs 0.000 claims 2
- 235000002538 magnesium citrate Nutrition 0.000 claims 2
- 239000004337 magnesium citrate Substances 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 210000003901 trigeminal nerve Anatomy 0.000 claims 2
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims 2
- 210000001364 upper extremity Anatomy 0.000 claims 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229910001425 magnesium ion Inorganic materials 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000004033 plastic Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562100862P | 2015-01-07 | 2015-01-07 | |
| EP16735422.4A EP3242676B1 (en) | 2015-01-07 | 2016-01-07 | Magnesium-containing oxytocin formulations and methods of use |
| PCT/US2016/012512 WO2016112205A1 (en) | 2015-01-07 | 2016-01-07 | Magnesium-containing oxytocin formulations and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231438T1 true HRP20231438T1 (hr) | 2024-06-07 |
Family
ID=56285908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231438TT HRP20231438T1 (hr) | 2015-01-07 | 2016-01-07 | Formulacije oksitocina koje sadrže magnezij i načini uporabe |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9629894B2 (enExample) |
| EP (2) | EP3242676B1 (enExample) |
| JP (3) | JP7030517B2 (enExample) |
| KR (1) | KR102677904B1 (enExample) |
| CN (1) | CN107847552B (enExample) |
| AU (3) | AU2016205225A1 (enExample) |
| CA (1) | CA2972975A1 (enExample) |
| DK (1) | DK3242676T3 (enExample) |
| ES (1) | ES2963707T3 (enExample) |
| FI (1) | FI3242676T3 (enExample) |
| HR (1) | HRP20231438T1 (enExample) |
| HU (1) | HUE065385T2 (enExample) |
| IL (1) | IL253347B (enExample) |
| LT (1) | LT3242676T (enExample) |
| MX (1) | MX388286B (enExample) |
| PL (1) | PL3242676T3 (enExample) |
| PT (1) | PT3242676T (enExample) |
| RS (1) | RS65034B1 (enExample) |
| RU (1) | RU2017127734A (enExample) |
| SG (1) | SG11201705591PA (enExample) |
| SI (1) | SI3242676T1 (enExample) |
| SM (1) | SMT202400020T1 (enExample) |
| WO (1) | WO2016112205A1 (enExample) |
| ZA (1) | ZA201705176B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7030517B2 (ja) * | 2015-01-07 | 2022-03-07 | トライジェミナ， インコーポレイテッド | マグネシウム含有オキシトシン製剤および使用の方法 |
| CN115814055A (zh) | 2016-04-12 | 2023-03-21 | 三叉神经股份公司 | 含镁催产素制剂和应用方法 |
| EP3681474B1 (en) * | 2017-09-11 | 2025-10-29 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Compositions and methods for nasal administration of drugs to brain and for systemic effect |
| US11970554B2 (en) | 2018-03-01 | 2024-04-30 | Tonix Pharmaceuticals Holding Corp. | Labeled oxytocin and method of manufacture and use |
| US20230414492A1 (en) * | 2019-04-02 | 2023-12-28 | Nose To Brain Therapeutics Llc | Intranasal delivery of cannabidiol to treat central nervous system disorders |
| US11241477B2 (en) | 2019-08-29 | 2022-02-08 | New York University | Oxytocin compositions for treatment of tinnitus |
| WO2022200568A1 (en) | 2021-03-26 | 2022-09-29 | Ot4B | Treatment of dysphagia |
| GB2607333A (en) * | 2021-06-03 | 2022-12-07 | Horopito Ltd | Pain relief composition |
| WO2023091469A1 (en) * | 2021-11-17 | 2023-05-25 | The Board Of Trustees Of The Leland Stanford Junior University | Targeting periosteal tissue for delivery of therapeutics |
| US20250255930A1 (en) * | 2024-02-08 | 2025-08-14 | Maskbegone Llc | Methods of treatment of tinnitus using derivatives of oxytocin |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE431291C (de) | 1925-03-29 | 1926-07-08 | Contessa Nettel A G | Wechselkassette mit herausziehbarer Wechsellade |
| US1936364A (en) | 1930-08-22 | 1933-11-21 | Pfizer Charles & Co | Citrate solutions |
| US2260004A (en) | 1939-11-03 | 1941-10-21 | Pfizer Charles & Co | Stable soluble magnesium acid citrate |
| US2938891A (en) | 1956-03-30 | 1960-05-31 | Roussel Uclaf | Method of making oxytocin and intermediates thereof |
| US3076797A (en) | 1957-07-22 | 1963-02-05 | Roussel Uclaf | Process of producing oxytocin and intermediates obtained thereby |
| US4213968A (en) | 1978-06-05 | 1980-07-22 | Coy David Howard | Enkephalin derivatives |
| US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
| US4486441A (en) | 1982-12-03 | 1984-12-04 | Merrell Toraude Et Compagnie | Pseudotropyl halogeno-benzoates and their use in migraine treatment |
| JPS59163313A (ja) | 1983-03-09 | 1984-09-14 | Teijin Ltd | 経鼻投与用ペプチドホルモン類組成物 |
| ATE78158T1 (de) | 1985-05-22 | 1992-08-15 | Liposome Technology Inc | Verfahren und system zum einatmen von liposomen. |
| HU906340D0 (en) | 1986-10-13 | 1991-04-29 | Sandoz Ag | Synthesis in solid phase for producing peptonic alcohols |
| KR890006252A (ko) | 1987-10-15 | 1989-06-12 | 헤르비그 폰 모르체 | 분말형 폴리펩타이드의 비강내 투여용 조성물 및 투여방법 |
| US4885287A (en) | 1988-08-09 | 1989-12-05 | University Of Kentucky Research Foundation | Novel method of administering aspirin and dosage forms containing same |
| US5624898A (en) | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
| US6407061B1 (en) | 1989-12-05 | 2002-06-18 | Chiron Corporation | Method for administering insulin-like growth factor to the brain |
| ATE156704T1 (de) | 1989-12-05 | 1997-08-15 | Ramsey Foundation | Neurologische wirkstoffe zur nasalen verabreichung an das gehirn |
| US5460972A (en) * | 1991-04-08 | 1995-10-24 | Research Foundation Of The State University Of New York | Ionized magnesium2+ concentrations in biological samples |
| GB9202464D0 (en) | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
| GB9203769D0 (en) | 1992-02-21 | 1992-04-08 | Sandoz Ltd | Improvements in or relating to organic compounds |
| GB9211268D0 (en) | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| DE4312913A1 (de) | 1992-10-23 | 1994-10-13 | Knauf Siegfried | Medikamentenzusammensetzung Oxytocin, Vasopressin und alphabetagamma-Endorphine |
| SE9300937L (sv) | 1993-03-19 | 1994-09-20 | Anne Fjellestad Paulsen | Komposition för oral administrering av peptider |
| DE69434418T2 (de) | 1993-04-22 | 2005-12-22 | Emisphere Technologies, Inc. | Orale Dareichungsform |
| US5482931A (en) | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
| US5837809A (en) | 1995-08-11 | 1998-11-17 | Oregon Health Sciences University | Mammalian opioid receptor ligand and uses |
| US6054462A (en) | 1994-04-13 | 2000-04-25 | Janssen Pharmaceutica, N.V. | Intranasal antimigraine compositions |
| JP3414539B2 (ja) | 1994-05-11 | 2003-06-09 | 有限会社ドット | 経鼻吸収用組成物 |
| WO1996020001A1 (en) | 1994-12-28 | 1996-07-04 | Teikoku Hormone Mfg. Co., Ltd. | Transmucosal preparation |
| US5849761A (en) | 1995-09-12 | 1998-12-15 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
| CA2247191C (en) * | 1996-02-27 | 2005-01-04 | Teijin Limited | Powdery composition for nasal administration |
| DE19627228A1 (de) | 1996-07-05 | 1998-01-08 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung für Medien |
| US5914129A (en) | 1996-07-23 | 1999-06-22 | Mauskop; Alexander | Analgesic composition for treatment of migraine headaches |
| US5798266A (en) | 1996-08-27 | 1998-08-25 | K-Quay Enterprises, Llc | Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer |
| US5855907A (en) | 1997-03-24 | 1999-01-05 | Peyman; Gholam A. | Method of treatment of migraine |
| SE9701162D0 (sv) | 1997-03-27 | 1997-03-27 | Karolinska Innovations Ab | New use II |
| SE9701161D0 (sv) | 1997-03-27 | 1997-03-27 | Karolinska Innovations Ab | New use I |
| AU8333998A (en) | 1997-07-15 | 1999-02-10 | Novo Nordisk A/S | New use of nociceptin |
| US6432986B2 (en) | 1997-07-21 | 2002-08-13 | Bruce H. Levin | Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches |
| US20030185761A1 (en) | 1997-10-01 | 2003-10-02 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
| US6143278A (en) | 1998-02-23 | 2000-11-07 | Elkhoury; George F. | Topical application of opioid analgesic drugs such as morphine |
| US6090368A (en) | 1998-03-03 | 2000-07-18 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine |
| EP1950224A3 (en) | 1998-03-09 | 2008-12-17 | Zealand Pharma A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| US6068999A (en) | 1998-06-25 | 2000-05-30 | Hendrix; Curt | Dietary supplement for supporting cerebrovascular tone and treating migraine headaches |
| US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
| JP2002531490A (ja) | 1998-12-09 | 2002-09-24 | カイロン コーポレイション | 中枢神経系に薬剤を投与するための方法 |
| JP2002531489A (ja) | 1998-12-09 | 2002-09-24 | カイロン コーポレイション | 中枢神経系への神経栄養剤の投与 |
| US7273618B2 (en) | 1998-12-09 | 2007-09-25 | Chiron Corporation | Method for administering agents to the central nervous system |
| US6139861A (en) | 1999-01-14 | 2000-10-31 | Friedman; Mark | Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm |
| KR20020016831A (ko) | 1999-06-16 | 2002-03-06 | 나스텍 파마수티컬 컴퍼니 인코포레이티드 | 비내용 모르핀을 함유하는 의약 조성물 및 그 제조방법 |
| JP2001002589A (ja) | 1999-06-18 | 2001-01-09 | Teijin Ltd | 穏やかな薬物血中濃度の上昇を可能とする経鼻投与用組成物 |
| JP2001089359A (ja) | 1999-09-24 | 2001-04-03 | Toko Yakuhin Kogyo Kk | 鎮痛成分の点鼻用ゲルまたはゾル製剤 |
| AU8003800A (en) * | 1999-10-08 | 2001-04-23 | Joyce Corinne Bechthold | Methods and compositions for treating neurobehavioral disorders |
| CA2325106A1 (en) | 1999-12-06 | 2001-06-06 | Stanley L. Gore | Compositions and methods for intranasal delivery of active agents to the brain |
| DE60021760T2 (de) | 1999-12-09 | 2006-06-08 | Chiron Corp., Emeryville | Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem |
| ATE290856T1 (de) | 1999-12-16 | 2005-04-15 | Dermatrends Inc | Hydroxide freisetzende verbindungen zum verbessern der hautdurchlässigkeit |
| US6413499B1 (en) | 2000-01-06 | 2002-07-02 | Bryan M. Clay | Methods and kits for maxillary dental anesthesia by means of a nasal deliverable anesthetic |
| JP2001233787A (ja) | 2000-02-04 | 2001-08-28 | Patents Exploitation Co Bv | 小・中サイズのペプチド含有薬学的組成物 |
| EP1121935B1 (en) | 2000-02-04 | 2008-08-13 | Patents Exploitation Company B.V. | Pharmaceutical composition containing a small or medium size peptide |
| WO2001079263A1 (en) | 2000-04-14 | 2001-10-25 | Nippon Shinyaku Co., Ltd. | Peptide derivatives and medicinal compositions |
| AU2001257326A1 (en) | 2000-04-28 | 2001-11-12 | Memorial Sloan-Kettering Cancer Center | Topical anesthetic/opioid formulations and uses thereof |
| US7084126B1 (en) | 2000-05-01 | 2006-08-01 | Healthpartners Research Foundation | Methods and compositions for enhancing cellular function through protection of tissue components |
| AU2001262992A1 (en) | 2000-05-10 | 2002-02-18 | University Of Kentucky Research Foundation | System and method for intranasal administration of opioids |
| IL137820A (en) | 2000-08-10 | 2009-06-15 | S I S Shulov Inst For Science | Pharmaceutical composition for topical administration comprising an analgesic peptide |
| AU2002211688A1 (en) | 2000-10-13 | 2002-04-29 | Chiron Corporation | Method for treating ischemic events affecting the central nervous system |
| US20070112052A9 (en) | 2001-01-05 | 2007-05-17 | Larry Caldwell | Methods and compositions for treating headache pain with topical NSAID compositions |
| DE60236496D1 (de) | 2001-03-23 | 2010-07-08 | Einstein Coll Med | Verfahren zur erhöhung der analgetischen wirkung und zur verringerung der unerwünschten exitatorischen wirkungen von bimodalisch wirksamen opioidagonisten durch die hemmung von gm1-gangliosid |
| US20020169102A1 (en) | 2001-04-03 | 2002-11-14 | Frey William H. | Intranasal delivery of agents for regulating development of implanted cells in the CNS |
| JP2004532849A (ja) | 2001-04-20 | 2004-10-28 | カイロン コーポレイション | 中枢神経系へのポリヌクレオチド薬剤の送達 |
| US7820688B2 (en) | 2001-04-27 | 2010-10-26 | Memorial Sloan-Kettering Cancer Center | Topical anesthetic/opioid formulations and uses thereof |
| SE0102184D0 (sv) | 2001-06-19 | 2001-06-19 | Uvnaes Moberg Kerstin | New subject-matter |
| AU2002349513B2 (en) | 2001-11-26 | 2007-10-18 | Asubio Pharma Co., Ltd. | Medicinal compositions for nasal absorption |
| US20030104085A1 (en) | 2001-12-05 | 2003-06-05 | Yeomans David C. | Methods and compositions for treating back pain |
| JP2005524649A (ja) | 2002-02-25 | 2005-08-18 | カイロン コーポレーション | Ｍｃ４−ｒアゴニストの鼻腔内投与 |
| US7666876B2 (en) | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
| US7074426B2 (en) | 2002-03-27 | 2006-07-11 | Frank Kochinke | Methods and drug delivery systems for the treatment of orofacial diseases |
| US20040105889A1 (en) | 2002-12-03 | 2004-06-03 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
| CA2785889A1 (en) | 2002-04-22 | 2003-10-30 | The Board Of Trustees Of The Leland Stanford Junior University | Peptide inhibitors of protein kinase c |
| GB0209494D0 (en) | 2002-04-25 | 2002-06-05 | Optinose As | Nasal devices |
| ES2348604T3 (es) | 2002-04-29 | 2010-12-09 | Euro-Celtique S.A. | Péptidos conformacionalmente restringidos que se unen al receptor orl-1. |
| WO2003093816A2 (en) | 2002-05-02 | 2003-11-13 | Bayer Healtchare Ag | Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr) |
| EP2283864A1 (en) | 2002-07-16 | 2011-02-16 | Elan Pharma International Ltd. | Liquid dosage compositions fo stable nanoparticulate active agents |
| WO2004019875A2 (en) | 2002-08-30 | 2004-03-11 | Board Of Regents, The University Of Texas System | Non-invasive methods to identify agents for treating pain |
| ITMI20022022A1 (it) | 2002-09-24 | 2004-03-25 | Girolamo Calo' | Analoghi di nocicettina. |
| ES2353690T3 (es) | 2002-10-03 | 2011-03-04 | Neuropharmacology Services, Llc | Oxitocina para su uso en el tratamiento del autismo y del trastorno de asperger. |
| WO2004062563A2 (en) | 2003-01-16 | 2004-07-29 | Université de Lausanne | Methods for screening for therapeutic agents that are useful in the treatment of oxytocin and vasopressin-related disorders |
| US20070016968A1 (en) | 2003-02-19 | 2007-01-18 | Stephanos Kyrkanides | Treatment of pain through expression of opioid receptors |
| ES2315455T3 (es) | 2003-03-27 | 2009-04-01 | Pantarhei Bioscience B.V. | Uso de estrogenos para el tratamiento de infertilidad en maniferos machos. |
| WO2005046569A2 (en) | 2003-04-08 | 2005-05-26 | Biotempt B.V. | Pharmaceutical compositions for the treatment of sars |
| GB0319119D0 (en) * | 2003-08-14 | 2003-09-17 | Optinose As | Delivery devices |
| US20050153885A1 (en) | 2003-10-08 | 2005-07-14 | Yun Anthony J. | Treatment of conditions through modulation of the autonomic nervous system |
| GB0326632D0 (en) | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
| US20050228023A1 (en) | 2003-12-19 | 2005-10-13 | Sri International | Agonist and antagonist ligands of the nociceptin receptor |
| WO2005115370A2 (en) | 2004-04-23 | 2005-12-08 | The Regents Of The University Of California | Compounds and methods for treating non-inflammatory pain using pparalpha agonists |
| EP1604655A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| US7618615B2 (en) | 2004-08-13 | 2009-11-17 | Healthpartners Research Foundation | Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia |
| US7151084B2 (en) * | 2004-12-27 | 2006-12-19 | Miller Landon C G | Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes |
| CA2588292C (en) | 2004-12-01 | 2019-01-15 | Health Protection Agency | Non-cytotoxic protein conjugates |
| WO2006091332A2 (en) | 2005-02-23 | 2006-08-31 | Alza Corporation | Intranasal administration of active agents to the central nervous system |
| CN101193626A (zh) | 2005-03-11 | 2008-06-04 | 益德威士医药股份有限公司 | 奥曲肽的受控释放制剂 |
| US20060252685A1 (en) | 2005-05-04 | 2006-11-09 | Gould Jeffrey D | Treatment for sleep apnea |
| EP1928484B1 (en) * | 2005-08-26 | 2010-02-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treatment of headaches by administration of oxytocin |
| US9125833B2 (en) | 2005-11-02 | 2015-09-08 | Relmada Therapeutics, Inc. | Multimodal abuse resistant and extended release opioid formulations |
| EP1897543A1 (en) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine- wafer for drug substitution therapy |
| US9023793B2 (en) | 2006-09-29 | 2015-05-05 | Retrophin, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
| US8142803B2 (en) | 2007-03-22 | 2012-03-27 | Magceutics, Inc. | Magnesium compositions and uses thereof for neurological disorders |
| US9808509B2 (en) | 2007-06-08 | 2017-11-07 | Healthpartners Research Foundation | Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system |
| JP2009073744A (ja) | 2007-09-19 | 2009-04-09 | Saitama Medical Univ | 片頭痛の予防治療剤 |
| EP2161030A1 (en) | 2008-09-09 | 2010-03-10 | Rijksuniversiteit te Groningen | Oxytocin formulations and uses thereof |
| JP5467785B2 (ja) | 2009-03-25 | 2014-04-09 | 大塚製薬株式会社 | 抗鳥インフルエンザウイルス抗体の産生促進剤 |
| KR20180052610A (ko) * | 2009-07-27 | 2018-05-18 | 노시셉터 엘엘씨 | 통증 치료 방법 |
| JP5491119B2 (ja) | 2009-10-02 | 2014-05-14 | 日東電工株式会社 | 薬物含有微粒子を含む医薬組成物およびその製造方法 |
| US20130130985A1 (en) * | 2010-04-01 | 2013-05-23 | Paul Alewood | Oxytocin peptide analogues |
| AU2011264416A1 (en) | 2010-06-07 | 2013-01-10 | The University Of Queensland | Nociceptin mimetics |
| WO2012016229A2 (en) * | 2010-07-30 | 2012-02-02 | The Regents Of The University Of California | Oxytocin treatment to improve memory and modify blood glucose |
| JO3400B1 (ar) | 2010-09-30 | 2019-10-20 | Ferring Bv | مركب صيدلاني من كاربيتوسين |
| US20120252894A1 (en) * | 2011-04-01 | 2012-10-04 | Giniatullin Rashid | Compounds for alleviating pain and stress in fetus and newborn |
| SE536091C2 (sv) | 2011-04-14 | 2013-04-30 | Pep Tonic Medical Ab | Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter |
| EP2908840A1 (en) * | 2012-10-12 | 2015-08-26 | Peptonic Medical AB | Novel use of a composition comprising oxytocin |
| US20140147519A1 (en) | 2012-11-26 | 2014-05-29 | Larry A. MCPHAIL | Migraine Treatment |
| JP7030517B2 (ja) * | 2015-01-07 | 2022-03-07 | トライジェミナ， インコーポレイテッド | マグネシウム含有オキシトシン製剤および使用の方法 |
-
2016
- 2016-01-07 JP JP2017535877A patent/JP7030517B2/ja active Active
- 2016-01-07 MX MX2017008913A patent/MX388286B/es unknown
- 2016-01-07 CA CA2972975A patent/CA2972975A1/en active Pending
- 2016-01-07 SI SI201631762T patent/SI3242676T1/sl unknown
- 2016-01-07 RS RS20240018A patent/RS65034B1/sr unknown
- 2016-01-07 WO PCT/US2016/012512 patent/WO2016112205A1/en not_active Ceased
- 2016-01-07 RU RU2017127734A patent/RU2017127734A/ru not_active Application Discontinuation
- 2016-01-07 FI FIEP16735422.4T patent/FI3242676T3/fi active
- 2016-01-07 EP EP16735422.4A patent/EP3242676B1/en active Active
- 2016-01-07 KR KR1020177021998A patent/KR102677904B1/ko active Active
- 2016-01-07 SM SM20240020T patent/SMT202400020T1/it unknown
- 2016-01-07 HR HRP20231438TT patent/HRP20231438T1/hr unknown
- 2016-01-07 US US14/990,529 patent/US9629894B2/en active Active
- 2016-01-07 ES ES16735422T patent/ES2963707T3/es active Active
- 2016-01-07 PT PT167354224T patent/PT3242676T/pt unknown
- 2016-01-07 HU HUE16735422A patent/HUE065385T2/hu unknown
- 2016-01-07 CN CN201680013809.5A patent/CN107847552B/zh active Active
- 2016-01-07 PL PL16735422.4T patent/PL3242676T3/pl unknown
- 2016-01-07 LT LTEPPCT/US2016/012512T patent/LT3242676T/lt unknown
- 2016-01-07 US US15/541,991 patent/US11389473B2/en active Active
- 2016-01-07 EP EP23201255.9A patent/EP4331670A3/en active Pending
- 2016-01-07 AU AU2016205225A patent/AU2016205225A1/en not_active Abandoned
- 2016-01-07 DK DK16735422.4T patent/DK3242676T3/da active
- 2016-01-07 SG SG11201705591PA patent/SG11201705591PA/en unknown
-
2017
- 2017-07-06 IL IL253347A patent/IL253347B/en unknown
- 2017-07-31 ZA ZA2017/05176A patent/ZA201705176B/en unknown
-
2020
- 2020-12-09 AU AU2020286221A patent/AU2020286221B2/en active Active
-
2021
- 2021-11-02 JP JP2021179295A patent/JP7455402B2/ja active Active
-
2024
- 2024-03-06 JP JP2024033983A patent/JP7756953B2/ja active Active
- 2024-05-23 AU AU2024203428A patent/AU2024203428A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231438T1 (hr) | Formulacije oksitocina koje sadrže magnezij i načini uporabe | |
| JP2018502856A5 (enExample) | ||
| HRP20240485T1 (hr) | Pripravci glp-1 i njihova upotreba | |
| PH12017500479B1 (en) | Liquid inhalation formulation comprising rpl554 | |
| HRP20211198T1 (hr) | Modulatori proteina regulatora transmembranske vodljivosti kod cistične fibroze i postupci upotrebe | |
| HRP20200889T1 (hr) | Upotreba dugodjelujućih peptida glp-1 | |
| HRP20191777T1 (hr) | Vodena farmaceutska formulacija tapentadola za oralnu primjenu | |
| BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
| HRP20190777T1 (hr) | Brzodjelujući pripravci inzulina | |
| HRP20221367T1 (hr) | Brzodjelujući inzulinski pripravci | |
| KR20150011807A (ko) | 자일리톨계 항-점액성 조성물과 관련 방법 및 조성물 | |
| HRP20240166T1 (hr) | Postupak liječenja prader-willijevog sindroma | |
| HRP20130920T1 (hr) | Postupak uporabe antagonista vazopresina s kemoterapijom antraciklina radi snižavanja kardiotoksiäśnosti i/ili poboljšanja stope preživljavanja | |
| JP2011520894A5 (enExample) | ||
| ATE507818T1 (de) | Orale verabreichung eines calcitonins | |
| ZA201901370B (en) | Formulations for oral administration of active agents | |
| MX2019005342A (es) | Tratamiento de enfermedades del sistema nervioso central (snc) con estimulantes de guanilato ciclas solubles (sgc). | |
| JP2022003099A5 (enExample) | ||
| MX388825B (es) | Uso y dosificacion de agentes terapeuticos para endometriosis. | |
| HRP20181079T1 (hr) | Sirnk i njena primjena u metodama i kompozicijama za liječenje i/ili prevenciju očnih stanja | |
| HRP20201726T1 (hr) | Liječenje valunga i gubitka kostiju izazvanih terapijom uskraćivanja androgena pomoću cis-klomifena | |
| HRP20191243T1 (hr) | Topikalni antifugalni pripravak za liječenje onihomikoze | |
| RU2014130894A (ru) | Пептид, обладающий нейропротекторной и ноотропной активностью, и фармацевтическая композиция на его основе | |
| NZ771693B2 (en) | Magnesium-containing oxytocin formulations and methods of use | |
| NZ734097B2 (en) | Magnesium-containing oxytocin formulations and methods of use |